EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Direct Oral Anticoagulant Consumption and the Risk of Acute Interstitial Lung Diseases: A Case‐Crossover Study Using Japanese Administrative Data

Keisuke Anan, Takahiro Itaya, Yuki Kataoka iD, Kazuya Ichikado, Kodai Kawamura, Yosuke Yamamoto

Pharmacoepidemiology and Drug Safety · 2026-06 · 35 (6)

DOI: 10.1002/pds.70398 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, online erschienen am 23.05.2026. Verfasst von Keisuke Anan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Healthcare Epidemiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Hauptthemen laut MEDLINE: Anticoagulants, Factor Xa Inhibitors, Hospitalization, Lung Diseases, Interstitial. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Institute of Healthcare Data Science, Japan Society for the Promotion of Science (JSPS), Saiseikai Kumamoto Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Direct oral anticoagulants (DOACs) offer advantages over warfarin; however, concerns exist regarding their association with acute interstitial lung diseases (ILDs). This study investigated the risk of acute‐onset ILDs associated with DOAC use.

Methods

We conducted a case‐crossover study to assess the risk of hospitalization for acute‐onset ILDs following DOAC initiation using the JMDC database, a Japanese administrative claims database. Patients aged ≥ 18 years hospitalized for acute‐onset ILDs (April 2011–February 2023) were included. DOAC exposure was defined as ≥ 14 days within predefined 30‐day windows: 1–30 days before admission (exposure period) and 60–90 and 120–150 days before admission (reference periods). The primary outcome was hospitalizations for acute‐onset ILD, identified using a validated algorithm. Conditional logistic regression estimated odds ratios (ORs). Sensitivity analyses included a bidirectional case‐crossover design, a case‐crossover analysis with warfarin as an active comparator, weighted case‐crossover analysis, and a case–case‐time‐control design. A descriptive cohort analysis of new DOAC and warfarin users examined ILD frequency and prognosis.

Results

The main case‐crossover analysis included 178 patients, showing an association between DOAC use and acute‐onset ILDs (adjusted OR, 4.44 [95% CI, 1.58–12.5]). Sensitivity analyses demonstrated a consistent direction of association (adjusted ORs: 3.37–6.85). In descriptive cohort analysis (52 021 DOAC and 12 026 warfarin initiators), ILD incidence was low (0.24% vs. 0.20%), but 90‐day mortality was higher in the DOAC group (21% vs. 0%).

Conclusions

DOAC use was associated with an increased risk of hospitalization for acute‐onset ILDs. Clinicians should monitor patients on DOACs for ILD symptoms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsFactor Xa InhibitorsHospitalizationLung Diseases, InterstitialAgedAged, 80 and overFemaleHumansMaleMiddle AgedAcute DiseaseAdministration, OralCase-Control StudiesCross-Over StudiesDatabases, FactualJapanRisk FactorsWarfarin

Stichwörter der Autor:innen

administrative datacase‐crossover designdirect oral anticoagulantinterstitial lung disease

Substanzen

AnticoagulantsFactor Xa InhibitorsWarfarin

Autor:innen und Institutionen

  • Department of Healthcare Epidemiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Division of Respiratory Medicine, Saiseikai Kumamoto Hospital, Kumamoto, Japan.
  • Clinical Research Management Section, Saiseikai Kumamoto Hospital, Kumamoto, Japan.
  • Scientific Research Works Peer Support Group (SRWS-PSG), Osaka, Japan.
  • Department of Internal Medicine, Kyoto Min-Iren Asukai Hospital, Kyoto, Japan.
  • Center for Postgraduate Clinical Training and Career Development, Nagoya University Hospital, Nagoya, Japan.

ORCID-Profile: Yuki Kataoka

Förderung

  • Research Institute of Healthcare Data Science
  • Japan Society for the Promotion of Science (JSPS)
  • Saiseikai Kumamoto Hospital

Zitieren

APA

Anan, K., Itaya, T., Kataoka, Y., Ichikado, K., Kawamura, K., & Yamamoto, Y. (2026). Direct Oral Anticoagulant Consumption and the Risk of Acute Interstitial Lung Diseases: A Case‐Crossover Study Using Japanese Administrative Data. Pharmacoepidemiology and Drug Safety, 35(6). https://doi.org/10.1002/pds.70398

Vancouver

Anan K, Itaya T, Kataoka Y, Ichikado K, Kawamura K, Yamamoto Y. Direct Oral Anticoagulant Consumption and the Risk of Acute Interstitial Lung Diseases: A Case‐Crossover Study Using Japanese Administrative Data. Pharmacoepidemiology and Drug Safety. 2026;35(6). doi:10.1002/pds.70398

BibTeX
@article{Anan2026,
  author = {Anan, Keisuke and Itaya, Takahiro and Kataoka, Yuki and Ichikado, Kazuya and Kawamura, Kodai and Yamamoto, Yosuke},
  title = {Direct Oral Anticoagulant Consumption and the Risk of Acute Interstitial Lung Diseases: A Case‐Crossover Study Using Japanese Administrative Data},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2026},
  volume = {35},
  number = {6},
  doi = {10.1002/pds.70398}
}
Kostenlos starten →